CEMQ:F:F-iShares Edge MSCIope Quality Factor UCITS (EUR)

ETF | Others |

Last Closing

USD 10.5

Change

+0.05 (+0.48)%

Market Cap

USD 0.47B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.07 (+0.14%)

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

+4.82 (+0.78%)

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.09 (+0.17%)

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.12 (+0.76%)

USD 63.18B
VUSA:F Vanguard Funds Public Limited ..

+1.09 (+0.99%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+1.09 (+0.98%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

-0.06 (-0.73%)

USD 43.12B
0ZC:F Zscaler Inc

+2.94 (+1.63%)

USD 37.92B

ETFs Containing CEMQ:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.90% 74% C 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.90% 74% C 63% D
Trailing 12 Months  
Capital Gain 8.85% 48% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.85% 43% F 47% F
Trailing 5 Years  
Capital Gain 37.52% 66% D+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.52% 65% D 49% F
Average Annual (5 Year Horizon)  
Capital Gain 11.24% 72% C 67% D+
Dividend Return 11.24% 70% C- 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.24% 51% F 84% B
Risk Adjusted Return 84.86% 84% B 88% B+
Market Capitalization 0.47B 61% D- 47% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike